UMRX Key Statistics, Chart & Performance
The current stock price of UMRX is 2.35 null. In the past month the price increased by 6.82%. In the past year, price increased by 67.86%.
UMRX Latest News, Press Relases and Analysis
About UMRX
Company Profile
Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States.
Company Info
Unum Therapeutics Inc
200 CAMBRIDGE PARK DRIVE SUITE 3100
CAMBRIDGE MA 02140
CEO: Charles Wilson
Phone: 617-945-5576
Unum Therapeutics Inc / UMRX FAQ
What does Unum Therapeutics Inc do?
Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States.
What is the stock price of Unum Therapeutics Inc today?
The current stock price of UMRX is 2.35 null. The price increased by 0.43% in the last trading session.
Does Unum Therapeutics Inc pay dividends?
UMRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of UMRX stock?
UMRX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of Unum Therapeutics Inc (UMRX)?
Unum Therapeutics Inc (UMRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.76).
What is the ownership structure of Unum Therapeutics Inc (UMRX)?
You can find the ownership structure of Unum Therapeutics Inc (UMRX) on the Ownership tab.
UMRX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to UMRX. When comparing the yearly performance of all stocks, UMRX is one of the better performing stocks in the market, outperforming 79.87% of all stocks.
UMRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to UMRX. UMRX may be in some trouble as it scores bad on both profitability and health.
UMRX Financial Highlights
Over the last trailing twelve months UMRX reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 44.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -96.84% | ||
| ROA | -74.43% | ||
| ROE | N/A | ||
| Debt/Equity | 0.18 |